AXSM Quote, Financials, Valuation and Earnings

Biogen has a net margin of -63.08% compared to Axsome Therapeutics's net margin of 10.87%. Axsome Therapeutics's return on equity of -244.32% beat Biogen's return on equity of 10.33%.

Axsome Therapeutics has a consensus price target of $172.47, signalling upside risk potential of 57.15%. On the other hand Biogen has an analysts' consensus of $200.12 which suggests that it could grow by 52.39%. Given that Axsome Therapeutics has higher upside potential than Biogen, analysts believe Axsome Therapeutics is more attractive than Biogen.

Axsome Therapeutics has a beta of 0.883, which suggesting that the stock is 11.73% less volatile than S&P 500. In comparison Biogen has a beta of 0.057, suggesting its less volatile than the S&P 500 by 94.303%.

Axsome Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics pays -- of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend.

Axsome Therapeutics quarterly revenues are $118.8M, which are smaller than Biogen quarterly revenues of $2.5B. Axsome Therapeutics's net income of -$74.9M is lower than Biogen's net income of $266.7M. Notably, Axsome Therapeutics's price-to-earnings ratio is -- while Biogen's PE ratio is 11.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics is 13.63x versus 1.98x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

Phathom Pharmaceuticals has a net margin of -63.08% compared to Axsome Therapeutics's net margin of -250.98%. Axsome Therapeutics's return on equity of -244.32% beat Phathom Pharmaceuticals's return on equity of --.

Axsome Therapeutics has a consensus price target of $172.47, signalling upside risk potential of 57.15%. On the other hand Phathom Pharmaceuticals has an analysts' consensus of $21.13 which suggests that it could grow by 284.79%. Given that Phathom Pharmaceuticals has higher upside potential than Axsome Therapeutics, analysts believe Phathom Pharmaceuticals is more attractive than Axsome Therapeutics.

Axsome Therapeutics has a beta of 0.883, which suggesting that the stock is 11.73% less volatile than S&P 500. In comparison Phathom Pharmaceuticals has a beta of 0.351, suggesting its less volatile than the S&P 500 by 64.87%.

Axsome Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phathom Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics pays -- of its earnings as a dividend. Phathom Pharmaceuticals pays out -- of its earnings as a dividend.

Axsome Therapeutics quarterly revenues are $118.8M, which are larger than Phathom Pharmaceuticals quarterly revenues of $29.7M. Axsome Therapeutics's net income of -$74.9M is lower than Phathom Pharmaceuticals's net income of -$74.5M. Notably, Axsome Therapeutics's price-to-earnings ratio is -- while Phathom Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics is 13.63x versus 6.28x for Phathom Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Rhythm Pharmaceuticals has a net margin of -63.08% compared to Axsome Therapeutics's net margin of -103.5%. Axsome Therapeutics's return on equity of -244.32% beat Rhythm Pharmaceuticals's return on equity of -178.94%.

Axsome Therapeutics has a consensus price target of $172.47, signalling upside risk potential of 57.15%. On the other hand Rhythm Pharmaceuticals has an analysts' consensus of $75.25 which suggests that it could grow by 44.82%. Given that Axsome Therapeutics has higher upside potential than Rhythm Pharmaceuticals, analysts believe Axsome Therapeutics is more attractive than Rhythm Pharmaceuticals.

Axsome Therapeutics has a beta of 0.883, which suggesting that the stock is 11.73% less volatile than S&P 500. In comparison Rhythm Pharmaceuticals has a beta of 2.321, suggesting its more volatile than the S&P 500 by 132.096%.

Axsome Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rhythm Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics pays -- of its earnings as a dividend. Rhythm Pharmaceuticals pays out -- of its earnings as a dividend.

Axsome Therapeutics quarterly revenues are $118.8M, which are larger than Rhythm Pharmaceuticals quarterly revenues of $41.8M. Axsome Therapeutics's net income of -$74.9M is lower than Rhythm Pharmaceuticals's net income of -$43.3M. Notably, Axsome Therapeutics's price-to-earnings ratio is -- while Rhythm Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics is 13.63x versus 24.36x for Rhythm Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

SpringWorks Therapeutics has a net margin of -63.08% compared to Axsome Therapeutics's net margin of -125.59%. Axsome Therapeutics's return on equity of -244.32% beat SpringWorks Therapeutics's return on equity of -46.69%.

Axsome Therapeutics has a consensus price target of $172.47, signalling upside risk potential of 57.15%. On the other hand SpringWorks Therapeutics has an analysts' consensus of $72.88 which suggests that it could grow by 56.65%. Given that Axsome Therapeutics has higher upside potential than SpringWorks Therapeutics, analysts believe Axsome Therapeutics is more attractive than SpringWorks Therapeutics.

Axsome Therapeutics has a beta of 0.883, which suggesting that the stock is 11.73% less volatile than S&P 500. In comparison SpringWorks Therapeutics has a beta of 0.787, suggesting its less volatile than the S&P 500 by 21.261%.

Axsome Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SpringWorks Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Axsome Therapeutics pays -- of its earnings as a dividend. SpringWorks Therapeutics pays out -- of its earnings as a dividend.

Axsome Therapeutics quarterly revenues are $118.8M, which are larger than SpringWorks Therapeutics quarterly revenues of $61.5M. Axsome Therapeutics's net income of -$74.9M is higher than SpringWorks Therapeutics's net income of -$77.3M. Notably, Axsome Therapeutics's price-to-earnings ratio is -- while SpringWorks Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Axsome Therapeutics is 13.63x versus 18.00x for SpringWorks Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.